Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05702853 · ClinicalTrials.gov registry record · Phase 1
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
A Phase 1 study of Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma, sponsored by Medical University of South Carolina.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT05702853 is a Phase 1 study of Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 27 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05702853, a Phase 1 study of Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Medical University of South Carolina.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Conditions Studied
Interventions
- DRUG Cyclophosphamide injection
- DRUG Fludarabine Injection
- BIOLOGICAL CD19-CD34t metabolically programmed CAR transduced T-cells
Study Locations (1)
South Carolina
- Hollings Cancer Center at Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2023-11-06 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05702853
The ClinicalTrials.gov registry entry for NCT05702853 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (85% lower). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide injection is the first listed.
NCT05702853 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.
Frequently Asked Questions
What is clinical trial NCT05702853 about?
NCT05702853 is a clinical study titled "Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL". This is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL)/small lymphocytic ...
What is the current status of trial NCT05702853?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2023-11-06. Estimated completion is 2026-12-30.
What conditions does trial NCT05702853 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT05702853?
The interventions under investigation include: Cyclophosphamide injection (DRUG), Fludarabine Injection (DRUG), CD19-CD34t metabolically programmed CAR transduced T-cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT05702853?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05702853 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Chronic Lymphocytic Leukemia
All registered trials for this condition
B-Cell Non-Hodgkin Lymphoma
All registered trials for this condition
South Carolina
All trials with a study site in South Carolina
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.